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DNA-demethylating agents have shown clinical anti-
tumor efficacy via an unknown mechanism of action.
Usinga combinationof experimental andbioinformat-
ics analyses in colorectal cancer cells, we demon-
strate that low-dose 5-AZA-CdR targets colorectal
cancer-initiating cells (CICs) by inducingviralmimicry.
This is associated with induction of dsRNAs derived
at least in part from endogenous retroviral elements,
activation of the MDA5/MAVS RNA recognition
pathway, and downstream activation of IRF7. Indeed,
disruption of virus recognition pathways, by individu-
ally knocking down MDA5, MAVS, or IRF7, inhibits
the ability of 5-AZA-CdR to target colorectal CICs
and significantly decreases 5-AZA-CdR long-term
growth effects. Moreover, transfection of dsRNA into
CICs can mimic the effects of 5-AZA-CdR. Together,
our results represent a major shift in understanding
the anti-tumor mechanisms of DNA-demethylating
agents and highlight the MDA5/MAVS/IRF7 pathway
as a potentially druggable target against CICs.
INTRODUCTION
Many tumor types are organized as a cellular hierarchy sus-
tained by a subpopulation of cancer-initiating cells (CICs) (Kreso
and Dick, 2014). These CICs possess unique features, including
long-term self-renewal, the ability to initiate tumor growth in
xenograft models, and the ability to differentiate into the bulk
of the tumor mass (Kreso and Dick, 2014). Colorectal cancer fol-
lows this hierarchical model and contains CICs (Dalerba et al.,
2007; O’Brien et al., 2007, 2012; Ricci-Vitiani et al., 2007). Colo-
rectal CICs are believed to play a major role in tumor relapse and
patient survival, suggesting that therapeutic strategies targeting
this cell population would be highly beneficial to patient outcome
(Kreso et al., 2014; Merlos-Sua´rez et al., 2011).
Recent work suggests that CICs can be targeted by epigenetic
therapies, including experimental BMI-1 inhibitors in colorectalcancers and FDA-approved DNA methylation inhibitors, such
as 5-aza-2-deoxycytidine (5-AZA-CdR) in hematological malig-
nancies (Kreso et al., 2014; Tsai et al., 2012). 5-AZA-CdR is a
cytidine analog that traps DNAmethyltransferases after incorpo-
ration into DNA, resulting in proteasomal degradation and global
DNA demethylation (Kelly et al., 2010).
There is an ongoing debate about the molecular mechanisms
underlying the clinical efficacy of 5-AZA-CdR and whether it
represents a direct consequence of its effect on global demethy-
lation (Issa and Kantarjian, 2009). Previous data suggest that
promoter demethylation, followed by gene re-activation of aber-
rantly methylated tumor suppressor genes (TSGs), is a major
mechanism of 5-AZA-CdR anti-tumor effects (Navada et al.,
2014). This is in line with the finding that many TSG promoters
are hypermethylated in cancer cells and that cancer cells
become epigenetically addicted to DNA hypermethylation of a
set of TSGs (De Carvalho et al., 2012). More recently, we demon-
strated that gene-body DNA demethylation, followed by gene
repression of oncogenic pathways, may also play a role in the
cancer response to 5-AZA-CdR (Yang et al., 2014). However,
the prolonged time to response observed in patients and the
fact that global DNA methylation profiling, neither pretreatment
nor during treatment, can predict response (Treppendahl et al.,
2014) suggests that themajor molecular mechanisms underlying
the clinical efficacy of 5-AZA-CdRmay lie beyond demethylation
of TSG promoters and oncogene gene-bodies.
Here, we describe that transient low-dose exposure to 5-AZA-
CdR targets colorectal CICs by inducing double-stranded RNA
(dsRNA) expression, activation of the cytosolic pattern recogni-
tion receptor MDA5, and downstream activation of MAVS and
IRF7. This will lead to a ‘‘viral mimicry’’ state and is a major
molecular mechanism for the anti-tumor effect mediated by a
transient low dose of 5-AZA-CdR.RESULTS
Transient Low-Dose 5-AZA-CdR Induces Four Different
Profiles of Gene Expression
We have recently shown that transient treatment of HCT116
colorectal cancer cells with a low dose (0.3 mM) of 5-AZA-CdRCell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc. 961
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for 24 hr, followed by cell culture in a drug-free medium has a
long-term effect on population doubling time and colony-forma-
tion ability (Yang et al., 2014). Here, we used the same experi-
mental system to test the effects of transient treatment of
5-AZA-CdR on gene expression patterns. We monitored gene
expression patterns before and after treatment for up to
42 days after drug withdrawal. Using gene expression microar-
ray and consensus clustering to classify themost variable genes,
we identified four patterns of gene expression (Figures 1A and
S1A–S1C). Groups 1 and 2 are early-response genes that are
either downregulated (group 1) or upregulated (group 2) within
5 days of 5-AZA-CdR treatment, but return to the original expres-
sion level by the end of the follow-up period (42 days) (Figure 1A).
Using DNA methylation BeadChips, we observed that group 1
genes have a strong positive correlation between expression
and DNA methylation (Figures 1B and 1C), with most of the
DNA methylation changes occurring at gene bodies. Group 2
genes have a strong negative correlation between expression
and DNA methylation (Figures 1B and 1C). Group 3 is a small
and noisy group presenting no correlation between expres-
sion and DNA methylation (Figures 1A–1C). Group 4 genes are
late-response genes, where peak gene expression occurs
24 days after initial exposure to 5-AZA-CdR and higher gene
expression levels are observed even up to 42 days after drug
withdrawal (Figure 1A). This delayed activation and sustained
gene expression is compelling, since most clinical responses
to 5-AZA-CdR are delayed (Treppendahl et al., 2014). Group 4
genes have a weaker anti-correlation between expression and
DNA methylation, with a fat tail around the weak and no correla-
tion region (correlation coefficient, r; between 0.5 and +0.5;
Figures 1B and 1C), suggesting that several genes in this group
are activated by 5-AZA-CdR in the absence of direct changes in
DNA methylation of their promoters or coding regions. Most of
the genes in this group have low DNA methylation levels pre-
treatment (Figure 1C), suggesting that their activation by drug
treatment does not involve promoter DNA demethylation.
Late-Response Genes Are Enriched for Interferon-
Responsive Genes and the RIG1/MDA5 RNA-Sensing
Pathway
To identify the most significant canonical pathways associated
with the late-response genes (group 4), we performed an ingenu-
ity pathway analysis. Using Fisher’s right-tailed exact test, we
identified ‘‘interferon signaling’’ (p value = 5.3515; Figure S1D),Figure 1. Transient Low-Dose Treatment of 5-AZA-CdR Induces Dura
Enriched for Interferon-Responsive Genes and the RIG-1 Pathway
(A–E) HCT116 cells were transiently treated with 0.3 mMof 5-AZA-CdR for 24 hr (on
14, 24, and 42 after drug withdrawal and subjected to cDNA microarray. (A) An ex
the median value for each group, and the dotted lines are the lower quartile (lower
density plots showing the Pearson correlation (r) between gene expression and DN
axis indicates the density of probes. (C) Selected examples of genes from groups 1
The y axis represents the average expression level (left) and the average DNA
withdrawal. Error bars represent the SD. (D) The three most significant canonica
significance value for each canonical pathway was calculated by Fisher’s exact t
represent the ratio between the number of genes in group 4 that belong to that spe
(E) A diagram of the canonical pathway entitled ‘‘role of RIG1-like receptors in a
(MAVS) is a central node of the pathway, linking RIG-1/MDA5 receptors to IRF7.
See also Figure S1.‘‘activation of IRF by cytosolic pattern recognition receptors’’
(p value = 2.3712; Figure S4), and ‘‘role of RIG-1-like receptors
in antiviral innate immunity’’ (p value = 506, Figure 1E) as the top
three enriched canonical pathways at the ingenuity knowledge
database (Figure 1D). Interestingly, recent work reporting acti-
vation of interferon-responsive genes and the RIG1/MDA5
pathway after patient treatment with DNA methylation inhibitors
at low doses (Wrangle et al., 2013) highlights the clinical rele-
vance of our model system.
Although most of the genes in group 4 are responsive to type I
interferon (IFN) (Figures 1D and S1D), we could not detect any
IFNa or IFNb transcripts or protein as measured by qPCR and
ELISA in HCT116, LIM1215, and HT29 colorectal cancer cells
before or after a transient low dose of 5-AZA-CdR treatment.
Thus, this suggests that the cytosolic pattern recognition recep-
tors RIG1/MDA5 may be initiating the signaling cascade rather
than type I interferon. To test this hypothesis, we took advantage
of the fact that the RIG1/MDA5 signaling cascade depends on
the adaptor molecule MAVS (mitochondrial antiviral signaling,
also known as IPS1, CARDIF, and VISA) (Barbalat et al., 2011).
MAVS is an essential adaptor molecule that connects RIG1 and
MDA5 activation to the downstream activation of IRF3 and IRF7
(Figure 1E). Previous work has established that MAVS knock-
down blocks the RIG1/MDA5 signaling pathway (Barbalat et al.,
2011), allowing us to test the effect of low-dose 5-AZA-CdR treat-
ment when the RIG1/MDA5 signaling pathway is impaired.
First, we treated the B16-blueTM IFN-a/b Cells (InvivoGen)
with 5-AZA-CdR for 24 hours. B16-blue cells are stably trans-
fected with a SEAP (Secreted embryonic alkaline phosphatase)
reporter gene under the control of isg54 promoter enhanced
by a multimeric ISRE (interferon-sensitive response element)
and will respond to the activation of STAT1, STAT3, IRF3,
IRF7, and IRF9. Therefore, B16-blue cells can detect bioactive
type I IFNs by monitoring the activation of STAT1/2 (Figure S1D);
in addition, they can detect activation of the RIG1/MDA5
pathway by monitoring activation of IRF3/7 (Figure 1E).
We observed that upon transient low-dose 5-AZA-CdR expo-
sure, B16-blue cells initiate the strong activation of the SEAP re-
porter gene (Figure 2A). This 5-AZA-CdR-mediated activation of
the SEAP reporter gene was blocked by MAVS knockdown (Fig-
ures 2A, S2A, and S2B). These data highlight the importance of
RIG1/MDA5 cytosolic receptors in inducing the activities of inter-
feron-responsive promoters in response to 5-AZA-CdR treat-
ment. To test this further, we incubated untreated B16-blue cellsble and DNA Demethylation-Independent Activation of a Gene Set
e population doubling time). RNAwas extracted before treatment and at day 5,
pression profile for each of the four identified clusters. The solid line represents
dotted line) and the upper quartile (upper dotted line) for each group. (B) Kernel
Amethylation for each probe across the 42-day time course experiment. The y
, 2, 3, and 4 are shown. Left: the y axis represents the average expression level.
methylation level (right). The x axis denotes time (in days) after 5-AZA-CdR
l pathways enriched at group 4 genes using ingenuity pathway analysis. The
est right-tailed. The y axis displays the log of p value (left). The orange points
cific pathway by the total number of genes annotated to that specific pathway.
ntiviral innate immunity.’’ Genes highlighted in pink belong to group 4. IPS-1
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Figure 2. Transient Low-Dose Treatment of 5-AZA-CdR Induces Type III Interferon Production and Activation of MAVS
(A) B16-blue IFN-a/b cells (InvivoGen) were transiently treated with 0.3 mMof 5-AZA-CdR for 24 hr. Activity of the ISG54 promoter enhanced by amultimeric ISRE
was determined by measuring secreted alkaline phosphatase (SEAP). SEAP activity was measured at 640 nm when the QUANTI-blue substrate was provided.
The results presented are from three independent experiments. Error bars represent the SD of three independent experiments.
(B) Supernatants from B16 cells transiently treated with 5-AZA-CdR or transfected with 0.5 mg/ml of poly(I:C) were added to wild-type B16-blue IFN-a/b cells
(InvivoGen), and the presence of bioactive IFNs-a/bwas determined bymeasuring SEAP activity 24 hr after adding the supernatants. Error bars represent the SD
of three independent experiments.
(C) B16-blue IFN-a/b cells (InvivoGen) were transiently treated with 5-AZA-CdR in the presence or absence of the JAK1/JAK2 inhibitor Ruxolitinib (1 mM) or the
JAK3 inhibitor CP-690550 (1 mM). SEAP activity was measured at 640 nm.
(legend continued on next page)
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with supernatant derived from wild-type (WT) B16 cells after
5-AZA-CdR treatment. The supernatant alone was not able to
activate the SEAP reporter gene (Figure 2B), suggesting a lack
of bioactive type I IFNs in the supernatant of wild-type B16 cells
treated with 5-AZA-CdR. However, wild-type B16 cells trans-
fected with poly(I:C) (positive control) were able to release
type I IFNs in the supernatant, as shown by SEAP activation on
B16-blue cells (Figure 2B). To test whether other cytokines could
be playing a role in inducing the expression of interferon-respon-
sive genes in response to 5-AZA-CdR, we treated the B16-blue
cells with 5-AZA-CdR in the presence or absence of Ruxolitinib
(JAK1/JAK2 inhibitor) or CP-690550 (JAK3 inhibitor). In the pres-
ence of either Ruxolitinib or CP-690550, 5-AZA-CdR treatment
was no longer able to activate the SEAP reporter gene (Fig-
ure 2C). Since we could not detect type I IFNs and the B16-
blue cells do not respond to IFN-g, due to the inactivation of
the IFN-g receptor, these data suggest a potential role for
type III IFNs.
Similarly to the B16 murine model, we observed that the
co-treatment of 5-AZA-CdR with Ruxolitinib or CP-690550 was
sufficient to block the ability of 5-AZA-CdR to induce the expres-
sion of four interferon-responsive genes (group 4) in the human
colorectal cancer cell LIM1215 (Figure 2D), suggesting a poten-
tial role for type III IFNs. Indeed, we found that low-dose 5-AZA-
CdR treatment was able to significantly increase the expression
of the type III IFN IL29 in LIM1215, HCT116, and HT29 human
colorectal cancer cell lines (Figures 2E and S2G–S2I). 5-AZA-
CdR treatment also significantly increased the expression of
the type III IFN IL28a in the LIM1215 cell line (Figures 2F and
S2H–S2J). Altogether, our data suggest that transient low-
dose 5-AZA-CdR treatment can induce the expression of type
III, but not type I, IFNs, followed by a downstream activation of
interferon-stimulated genes (ISGs) in a JAK-dependent manner.
Interestingly, when we knocked down MAVS (Figures S2C–
S2F), wewere able to repress the ability of 5-AZA-CdR treatment
to induce type III IFNs (Figures 2E, 2F, and S2G–S2J), implicating
an upstream role for the cytosolic pattern recognition receptors
RIG1/MDA5 in initiating the signaling cascade induced by
5-AZA-Cd treatment that will culminate with type III IFNs and in-
crease in expression of ISGs.
The ability of the mitochondrial protein MAVS to transduce the
signal from the cytosolic pattern recognition receptors RIG1/
MDA5 and activation of downstream IRFs to induce the expres-
sion of IFNs is dependent on the formation of very large prion-like
aggregates of MAVS protein (Hou et al., 2011). To test whether
the 5-AZA-CdR treatment is indeed inducing activation of
RIG1/MDA5 and downstream signaling through MAVS, we
isolated the mitochondrial fraction of LIM1215 treated with
5-AZA-CdR or poly(I:C) (positive control) (Figure S2K) and per-
formed semi-denaturing detergent agarose gel electrophoresis(D) The LIM1215 colorectal cancer cell line was transiently treatedwith 5-AZA-CdR
JAK3 inhibitor CP-690550 (1 mM). Gene expression of four selected interferon-re
(E and F) LIM1215 with or without shRNA against MAVS were transiently treated
IL28a (F) was measured by quantitative real-time PCR at day 5.
(G) Mitochondrial extracts were prepared from LIM1215 cells treated with 5-AZA-C
extracts were analyzed by SDD-AGE. ****p < 0.0001; **p < 0.01 (one-way ANOV
See also Figure S2.(SDD-AGE), which has been previously shown to detect the
formation of MAVS prion-like aggregates (Hou et al., 2011). We
observed a smear of SDS-resistant high molecular weight
MAVS aggregates in our positive control, as well as the treated
cells, starting 1 day after 5-AZA-CdR treatment (Figure 2G), indi-
cating a functional activation of MAVS.
Activation of Late-Response Genes Is Dependent on
MDA5/MAVS/IRF7 Pathway Activation
Next, we sought to investigate the individual contributions of the
cytosolic pattern recognition receptors RIG1 and MDA5. We
knocked down RIG1 and MDA5 individually in LIM1215 cells
using validated small hairpin RNAs (shRNAs) (Figure 3A).
MDA5 knockdownwas sufficient to inhibit the activation of group
4 genes after 5-AZA-CdR treatment, while RIG1 knockdownwas
able to partially reduce the activation of group 4 genes (Fig-
ure 3A). This result suggests a major role for MDA5 in mediating
the downstream activation of MAVS after 5-AZA-CdR treatment.
Indeed, when we knocked down MAVS (Figures S2C–S2F), we
were also able to inhibit the activation of group 4 genes after
5-AZA-CdR treatment (Figures 3B, S3A, and S3B). It is important
to note that knockdown of MAVS had no effect on the ability
of 5-AZA-CdR to induce global DNA demethylation (Figures
S5E–S5G).
MAVS activation is known to activate several downstream
transcription factors, such as IRF1, IRF3, and IRF7 (Odendall
et al., 2014; Seth et al., 2005). Next, we investigated which
transcription factors are activated by MAVS in response to
5-AZA-CdR treatment. First, we performed IPA’s upstream reg-
ulators analysis (Kra¨mer et al., 2014) to identify transcription
factors predicted to be activated based on the activation Z score
of group 4 genes. We found IRF7 as one of the top predicted
transcription factors, with 20 known IRF7 direct target genes
also being upregulated in the group 4 gene set out of a total
of 98 known IRF7 direct targets (p value of overlap: 5.0915;
Figure 3C).
To validate that IRF7 was upregulated and activated, we per-
formed confocal microscopy on the LIM1215 colorectal cancer
cell line following 5-AZA-CdR treatment and observed increased
protein levels of IRF7 and a robust nuclear translocation (Fig-
ure 3D, second row), indicating activation of this transcription
factor. Moreover, in the presence of an impaired MDA5/MAVS
pathway, by knockdown of MAVS, 5-AZA-CdR treatment is no
longer sufficient to induce either IRF7 upregulation or activation,
as measured by nuclear translocation (Figure 3D, fourth row).
These data suggest that activation of interferon-responsive
genes by 5-AZA-CdR treatment is mediated by MDA5/MAVS-
dependent IRF7 activation, rather than by direct promoter
DNA demethylation. Indeed, group 4 genes downstream of
IRF7 have a significantly weaker anti-correlation between DNAin the presence or absence of the JAK1/JAK2 inhibitor Ruxolitinib (1 mM) or the
sponsive genes was measured by quantitative real-time PCR at day 5.
with 5-AZA-CdR. Gene expression of the type III interferon genes IL29 (E) and
dR for the indicated time, or transfected with poly(I:C), and then aliquots of the
A).
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Figure 3. Activation of Interferon-Responsive Genes by a Transient Low-Dose Treatment of 5-AZA-CdR Is Dependent on MDA5/MAVS/IRF7
Activation
(A and B) The LIM1215 colorectal cancer cell line with or without shRNA against RIG1 (A), MDA5 (A), or MAVS (B) was transiently treated with 5-AZA-CdR. Gene
expression of four selected interferon-responsive genes was measured by quantitative real-time PCR at day 5.
(C) Upstream regulators analysis using ingenuity pathway analysis reveals a significant overlap between group 4 genes and IRF7 direct target genes (p value:
5.09 3 1015).
(legend continued on next page)
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methylation and gene expression than the rest of the group 4
genes (Figure S3C; Kolmogorov-Smirnov test of frequency dis-
tribution data; p value = 0.0004). Furthermore, we evaluated
the DNA methylation levels of group 4 IRF7 downstream genes
(Figure 3C) in a set of 125 colorectal cancer samples from
different subgroups and 29 adjacent normal samples (Hinoue
et al., 2012). Consistent with our previous data, these genes
are largely unmethylated in primary samples, independent of
the tumor/normal status and independent of the CIMP (CpG
Island Methylator Phenotype) status (Figure S3D). Moreover,
5-AZA-CdR treatment did not induce IRF1 protein expression
(Figure S3E), and it did not increase the levels of IRF3 (Figure S3F)
or induce IRF3 nuclear translocation (Figure S3F), suggesting a
major role for IRF7. To confirm the role of IRF7, we knocked
down this transcription factor and observed that it was sufficient
to inhibit the activation of group 4 genes after 5-AZA-CdR treat-
ment (Figure 3E).
Altogether, our data suggest that transient low-dose 5-AZA-
CdR treatment can induce activation of interferon-responsive
genes by activating the MDA5/MAVS/IRF7 signaling pathway
in a process independent of promoter DNA demethylation of
interferon-responsive genes.
5-AZA-CdR Treatment Induces an Increase in dsRNAs
MDA5 is a cytosolic pattern-recognition receptor that recog-
nizes dsRNAs associated with virus infections (Barbalat et al.,
2011). Therefore, we investigated whether 5-AZA-CdR could
be inducing a significant increase in dsRNAs, explaining the acti-
vation of the MDA5/MAVS/IRF7 pathway. Using the J2 antibody,
a gold standard for dsRNA detection (Weber et al., 2006),
confocal microscopy showed a significant increase in dsRNAs
in LIM1215 cells starting 3 days after 5-AZA-CdR withdrawal
(Figures 4A–4D), persisting for up to 10 days after drug with-
drawal (Figures 4A–4D). Moreover, the second highest enriched
pathway, identified in Figure 1D, has two components: ‘‘Regula-
tion of innate immune response by RNA sensing molecules’’
and ‘‘Regulation of innate immune response by DNA sensing
molecules.’’ Remarkably, only the genes belonging to the
RNA-sensing pathway were upregulated by transient low-dose
5-AZA-CdR treatment (Figures S4A and S4B).
Itwas recently reported that endogenous retrovirus (ERV)RNAs
can trigger signaling by cytosolic pattern-recognition receptors
and activate MAVS in mammals (Zeng et al., 2014). Therefore,
we investigated whether ERVs could be the source of 5-AZA-
CdR-induced dsRNA and the trigger for the antiviral response.
Indeed,weobservedavery robustandsignificant increase in tran-
scription of human ERVs from classes previously described to
trigger aMAVS-mediated response (Zeng et al., 2014) (Figure 4E).
Then, using anRNaseA protection assay under high-salt concen-
tration (see theExperimental Procedures),weobserved that ERVs(D) Confocal microscopy of LIM1215 cells after treatment with a transient low-do
(DAPI). There is increased IRF7 expression and nuclear translocation in 5-AZA-C
(E) LIM1215 colorectal cancer cell line with or without shRNA against IRF7 was tra
responsive genes was measured by quantitative real-time PCR at day 5. The y axi
untreated control. Error bars represent the SD of at least three independent ex
ANOVA).
See also Figure S3.transcripts were hundreds to thousands of times more resistant
to RNase A digestion than a single-stranded RNA (ssRNA) gene
(b-actin) in 5-AZA-CdR-treated cells (Figure 4F).
5-AZA-CdR Effects on Tumor Cell Growth Are Largely
Dependent on the MDA5/MAVS/IRF7 Pathway
Transient low-dose 5-AZA-CdR treatment can decrease tumor
cell growth and reduce colony formation (Kelly et al., 2010;
Tsai et al., 2012; Yang et al., 2014). In order to test whether these
anti-tumor effects are mediated by activation of the MDA5/
MAVS/IRF7 pathway, we treated colorectal cancer cell lines
with or without individual knockdowns of MDA5, MAVS, and
IRF7. Population doubling time was monitored for up to
20 days, and we observed that the 5-AZA-CdR treatment ex-
erted a durable increase in the population doubling time in all
the three colorectal cancer cell lines as expected (Figures 5A–
5C and S5A–S5C). However, knockdown of MDA5, MAVS, or
IRF7 was sufficient to render these cells insensitive to 5-AZA-
CdR treatment (Figures 5A–5C and S5A–S5C), even though the
drug could still induce global DNA demethylation in the knock-
down cells (Figures S5E–S5G). Important to note, MAVS knock-
down alone has no major effect on population doubling time
(Figure S5D). Interestingly, RIG1 knockdown was not sufficient
to render these cells insensitive to drug treatment (Figure S5A),
again suggesting a major role for MDA5 rather than for RIG1 in
the response to 5-AZA-CdR treatment. These data suggest
that the long-term effects on population doubling time are largely
dependent on activation of the MDA5/MAVS/IRF7 pathway.
5-AZA-CdR Targets the Cancer-Initiating Compartment
by Activation of the MDA5/MAVS/IRF7 Pathway
Next, we tested whether 5-AZA-CdR can target cancer-initiating
cells (CICs), which are defined first and foremost by their ability to
self-renew. To calculate the sphere-initiating frequency, we used
the in vitro assay for sphere initiation followed by in vivo-limiting
dilution assays (LDAs), the gold standard assay for measuring
self-renewal (Kreso et al., 2014;Mack et al., 2014). For this assay,
we plated 1, 10, 100, or 1,000 cells per well in a 96-well round-
bottom plate for suspension cells, and after 4 weeks we counted
the number of positive wells (i.e., with formation of a spheroid)
(Figure 5D). Then we calculated the frequency of sphere-initi-
ating cells using the previously described ELDA algorithm (Hu
and Smyth, 2009). We used a pairwise chi-square test to calcu-
late whether the frequencies of sphere-initiating cells were
different between any two groups as previously described
(Hu and Smyth, 2009; Kreso et al., 2014; Mack et al., 2014).
Transient low-dose 5-AZA-CdR treatment induced a significant
10-fold reduction in the frequency of sphere-initiating cells (Fig-
ures 5E and 5F). However, inhibition of MDA5/MAVS/IRF7 acti-
vation by MAVS knockdown significantly reduced the ability ofse of 5-AZA-CdR. Total IRF7 is stained in green, and nuclei are stained in blue
dR-treated WT cells.
nsiently treated with 5-AZA-CdR. Gene expression of four selected interferon-
s represents the relative expression (in% of control) compared to the wild-type
periments. ns, non-significant; *p < 0.05; **p < 0.01; ****p < 0.0001 (one-way
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Figure 4. Increased dsRNA by a Transient Low-Dose Treatment of 5-AZA-CdR
(A) Confocal microscopy of LIM1215 cells 3 days after treatment with a transient low-dose of 5-AZA-CdR. Total dsRNA is stained in red, and nuclei are stained in
blue (DAPI). There is increased dsRNA expression in the cytoplasm of 5-AZA-CdR-treated cells.
(B–D) Quantification of dsRNA performed bymeasuring cell fluorescence using ImageJ 3 days (B), 5 days (C) or 10 days (D) after 5-AZA-CdR treatment. Corrected
total cell fluorescence (CTCF) was calculated using the following formula. CTCF = integrated density – (area of selected cell3mean fluorescence of background
readings). ****p < 0.0001, *p < 0.05 (two-tailed t test).
(E) LIM1215 was transiently treated with 5-AZA-CdR. The expression level of ten selected ERVs was measured by quantitative real-time PCR at day 5. ****p <
0.0001; ***p < 0.001; *p < 0.05 (two-way ANOVA).
(F) Total RNA was extracted from 5-AZA-CdR-treated cells. RNA was then digested or not with 50 mg/ml RNase A in high-salt concentration (NaCl, 0.35 M) for
30 min. Enrichment of dsRNA over ssRNA was then calculated by normalizing the delta Ct between RNase A treated and non-treated of ERVs (dsRNA) against
beta-actin (ssRNA). Error bars represent the SD of at least three independent experiments.
See also Figure S4.5-AZA-CdR to target sphere-initiating cells (Figures 5E and 5F;
p value = 0.000609), thereby suggesting that the effect of
5-AZA-CdR on self-renewal in the CIC fraction was dependent968 Cell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc.on MDA5/MAVS/IRF7 activation. Indeed, MDA5, but not RIG1,
knockdown completely inhibited the ability of 5-AZA-CdR to
target sphere-initiating cells (Figures S5H–S5J).
A B C
E F
Cell number
plated per well
Calculate
sphere-initiating
frequency
Fr
ac
tio
n 
Ne
ga
tiv
e
Number of cells
5-AZA-CdR
Mock
Culture for 4 weeksD LIM1215 (Control)
Co
ntr
ol 
(M
oc
k)
Co
ntr
ol 
(5-
AZ
A-
Cd
R)
0
10
20
30
40
50
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 2.74-15
LIM1215 (shMAVS)
sh
MA
VS
 (M
oc
k)
sh
MA
VS
 (5
-A
ZA
-C
dR
)
0
10
20
30
40
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 4.10-5
H IG
Fr
ac
tio
n 
Ne
ga
tiv
e
Number of cells
5-AZA-CdR
Mock
Tumor Grow for
4 months
Calculate
cancer-initiating
frequency
Cell number
injected per mice
LIM1215 (Control)
Co
ntr
ol 
(M
oc
k)
Co
ntr
ol 
(5-
AZ
A-
Cd
R)
0.001
0.010
0.100
1
in
 v
iv
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 1.55-5
LIM1215 (shMAVS)
sh
MA
VS
 (M
oc
k)
sh
MA
VS
 (5
-A
ZA
-C
dR
)
0.001
0.010
0.100
1
in
 v
iv
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = ns
0 5 10 15 20 25
0
100
200
300
400
Days After Treatment
D
ou
bl
in
g 
Ti
m
e
(%
 o
f c
on
tr
ol
)
Control
Sh MAVS 
*
**
*
*
0 5 10 15 20 25
0
100
200
300
400
Days After Treatment
D
ou
bl
in
g 
Ti
m
e
(%
 o
f c
on
tr
ol
)
Control
sh IRF7
*
**
**
0 5 10 15 20 25
0
100
200
300
400
Days After Treatment
D
ou
bl
in
g 
Ti
m
e
(%
 o
f c
on
tr
ol
)
Control
Sh MDA5
**
***
Figure 5. 5-AZA-CdR Effect on Cell Growth and Self-Renew Is Dependent on MDA5/MAVS/IRF7 Activation
(A–C) Population doubling time of LIM1215 with or without MDA5 (A), MAVS (B), and IRF7 (C) knockdown. The y axis denotes population doubling time (in hr) as a
percentage of the vehicle-treatedWT controls. The x axis represents time (in days) after 5-AZA-CdRwithdrawal. Error bars represent the SD of three independent
experiments.
(D) Schematic representation of the approach used to measure the sphere-initiating frequency after a transient low-dose 5-AZA-CdR treatment (see the
Experimental Procedures).
(E and F) Frequency of LIM1215 CICs before and after a low-dose transient 5-AZA-CdR treatment measured by in vitro limiting dilution assay in wild-type (E) or
shMAVS (F) cells. The y axis denotes the confidence intervals (lower, estimate and upper) for CIC frequency.
(G) Schematic representation of the approach used to measure the cancer-initiating cells frequency in vivo after a transient low-dose 5-AZA-CdR treatment (see
the Experimental Procedures).
(H and I) Frequency of LIM1215 CICs before and after a low-dose transient 5-AZA-CdR treatment measured by in vivo limiting dilution assay in wild-type (H) or
shMAVS (I) cells. The y axis denotes the confidence intervals (lower, estimate and upper) for CIC frequency. *p < 0.05; **p < 0.01; ***p < 0.001. Multiple t tests were
used to test for difference in population doubling time. A pairwise chi-square test was used to test for the difference in CIC frequency.
See also Figure S5.To validate our in vitro sphere-initiating results, we measured
self-renewal using an in vivo-limiting dilution assay. NSG mice
were injected subcutaneously with 10, 100, 1,000, 10,000, and
50,000 cells following a transient in vitro exposure to a low
dose of 5-AZA-CdR or vehicle control. The presence or
absence of tumors was assessed after 4 months so that the fre-
quency of colorectal CICs could be calculated (Figure 5G). Weobserved that a transient low dose of 5-AZA-CdR significantly
reduced colorectal CIC frequency in vivo (Figure 5H; p value =
0.0000155). However, blockage of MDA5/MAVS/IRF7 activation
by MAVS knockdown rendered colorectal CICs completely
insensitive to 5-AZA-CdR (Figure 5I).
We further investigated the potential of 5-AZA-CdR-mediated
activation of MDA5/MAVS/IRF7 to target colorectal CICs usingCell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc. 969
APatient-derived #92
(CIMPhigh)
Patient-derived #181
(CIMPlow)
Patient-derived #73
(non-CIMP)
B
D E
C
F G
0.4
0.2
0.0
0.2
0.4
0.6
0.8
1.0
Sample 92 - CIMPhigh (Control)
Co
ntr
ol 
(M
oc
k)
Co
ntr
ol 
(5-
AZ
A-
Cd
R)
0
10
20
30
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 0.000119
Sample 92 - CIMPhigh (shMAVS)
sh
MA
VS
 (M
oc
k)
sh
MA
VS
 (5
-A
ZA
-C
dR
)
0
10
20
30
40
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = ns
Sample 181 - CIMPlow (Control)
Co
ntr
ol 
(M
oc
k)
Co
ntr
ol 
(5-
AZ
A-
Cd
R)
0
20
40
60
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 1.49-13
Sample 181 - CIMPlow (shMAVS)
sh
MA
VS
 (M
oc
k)
sh
MA
VS
 (5
-A
ZA
-C
dR
)
0
10
20
30
40
50
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = ns
Sample 73 - non-CIMP (Control)
Co
ntr
ol 
(M
oc
k)
Co
ntr
ol 
(5-
AZ
A-
Cd
R)
0
10
20
30
40
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 3.47-6
Sample 73 - non-CIMP (shMAVS)
sh
MA
VS
 (M
oc
k)
sh
MA
VS
 (5
-A
ZA
-C
dR
)
0
10
20
30
40
50
in
 v
itr
o 
C
IC
 F
re
qu
en
cy
 (%
)
p = 0.00615
Figure 6. Transient 5-AZA-CdR Treatment Reduces the Frequency
of Primary Colorectal CICs Independent of CIMP Status, and This
Activity Is Dependent on MAVS Activation
(A) Colorectal patient-derived cells were classified according to their CpG Is-
landMethylator Phenotype (CIMP) into CIMPhigh (sample 92), CIMPlow (sample
181), and non-CIMP (sample 73). Primary tissue DNA methylation data and
CIMPclassificationswere obtained fromHinoue et al. (2012). A heatmapshows
the pairwise correlation using Spearman correlation method of each sample.
(B–G) The frequency of colorectal CICs before and after a low-dose transient
5-AZA-CdR treatment measured by an in vitro-limiting dilution assay in MAVS
970 Cell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc.primary colorectal cancer cells isolated at the time of surgical
resection and stored in our biobank. Colorectal cancer samples
can be divided into three major molecular subgroups based
on the CpG Island Methylator Phenotype: CIMPhigh, CIMPlow,
or non-CIMP (Hinoue et al., 2012). By matching the global DNA
methylation profile of our primary samples against publicly
available DNA methylation data from primary colorectal cancer
samples (Hinoue et al., 2012), we were able to classify our sam-
ples into the three DNA methylation subgroups (CIMPhigh, CIM-
Plow, and non-CIMP; Figure 6A). Primary colorectal cancer cells
were grown in a defined medium without serum, allowing for
enrichment of CICs as previously described (Kreso et al., 2014;
O’Brien et al., 2012). Using the same in vitro assay for sphere
initiation coupled with LDAs (Figure 5D), we observed that 5-
AZA-CdR treatment significantly reduced the frequency of
sphere-initiating cells in the CIMPhigh (Figure 6B), CIMPlow (Fig-
ure 6D), and non-CIMP (Figure 6F) cells. However, 5-AZA-
CdR-mediated depletion of sphere-initiating cells was
completely rescued when MAVS was knocked down in the CIM-
Phigh (Figures 6C, S6A, and S6D) and CIMPlow (Figures 6E, S6B,
and S6D) cells and partially rescued in the non-CIMP (Figures
6G, S6C, and S6D) cells. In agreement with our previous data,
the ability of 5-AZA-CdR treatment to reduce the frequency of
sphere-initiating cells in primary CRC samples was associ-
ated with a significant increase in dsRNA formation (Figures
S6E–S6J).
Altogether, our data suggest that the majority of cell-intrinsic
anti-tumor effects mediated by a transient low-dose 5-AZA-
CdR treatment are mediated by activation of MDA5/MAVS/
IRF7 pathway.
RIG1 andMDA5AreDruggable Candidates for Targeting
Colorectal CICs
Since low-dose 5-AZA-CdR treatment can target colorectal
CICs by activation of the MDA5/MAVS/IRF7 pathway, we next
investigated whether agonists to cytosolic pattern-recognition
receptors alone are sufficient to reduce CIC frequency. Both
RIG1 and MDA5 can recognize dsRNAs. RIG1 is preferentially
activated by low molecular weight (LMW) dsRNAs, while MDA5
is preferentially activated by high molecular weight (HMW)
dsRNAs (Kato et al., 2008). We transfected three primary
colorectal cancer cells belonging to different CIMP status with
LMW or HMW poly(I:C). Using the same in vitro assay for sphere
initiation coupled with LDAs (Figure 5D), we observed that
transfection of either LMW (RIG1 agonist) or HMW (MDA5
agonist) dsRNAs can significantly reduce the frequency of
sphere-initiating cells in the CIMPhigh (Figure 7A), CIMPlow (Fig-
ure 7B), and non-CIMP (Figure 7C) samples. However, agonists
for other innate pattern-recognition receptors, such as cGAMP
or flagellin, were unable to significantly reduce the frequency ofwild-type cells (B, D, and F) and in MAVS knocked-down (shMAVS) cells
(C, E, and G). Patient-derived cells obtained from CIMPhigh (sample 92) (B and
C), a CIMPlow (sample 181) (D and E), and non-CIMP (sample 73) (F and G)
were used. The y axis denotes the confidence intervals (lower, estimate and
upper) for CIC frequency. A pairwise chi-square test was used to test for the
difference in CIC frequency.
See also Figure S6.
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Figure 7. RIG1 or MDA5 Agonists Reduce the Frequency of Primary Colorectal CICs Independent of CIMP Status
(A–C) The frequency of colorectal CICs before and after transfection with 0.5 mg/ml of low molecular weight (LMW-RIG1 agonist) or high molecular weight
(HMW-MDA5 agonist) poly(I:C) measured by an in vitro-limiting dilution assay. Patient-derived cells obtained fromCIMPhigh (sample 92) (A), CIMPlow (sample 181)
(B), and non-CIMP (sample 73) (C) were used. The y axis denotes the confidence intervals (lower, estimate and upper) for CIC frequency. Pairwise chi-square test
was used to test for the difference in CIC frequency.
See also Figure S7.sphere-initiating cells in the CIMPhigh (Figure S7A), CIMPlow (Fig-
ure S7B), and non-CIMP (Figure S7C) samples, corroborating
our gene expression analysis, where we found enrichment only
for regulation of innate immune response by RNA-sensing mole-
cules (Figure S4).
These data suggest that the activation of RIG1 or MDA5 alone
is sufficient to target colorectal CICs, highlighting the potential of
these targets as druggable candidates to target colorectal CIC.
DISCUSSION
Recent clinical and experimental data have shown that low
doses of 5-AZA-CdR induce sustained anti-tumor effects
against solid cancers (Juergens et al., 2011; Tsai et al., 2012;
Yang et al., 2014). However, the clinical response to low doses
of DNA-demethylating agents in both solid tumors and MDS/
AML usually takes more than a month to occur (Ahuja et al.,
2014; Juergens et al., 2011; Treppendahl et al., 2014). This de-
layed response has led many people in the field to speculate
that non-cytotoxic mechanisms may be playing a role in patient
response. In addition, it has been suggested that this type of
epigenetic therapy may be specifically targeting the cancer-initi-
ating cell compartment (Ahuja et al., 2014; Tsai et al., 2012).
However, it remains unclear whether transient low doses of
5-AZA-CdR could be targeting CICs and whether it is a direct
consequence of its epigenetic effects.
Our data show that low doses of 5-AZA-CdR can significantly
reduce the frequency of colorectal CICs using enriched sphere
cultures derived from human colorectal cancer at the time of sur-
gical resection. Colorectal cancer is a heterogeneous disease
that can be classified into three main subgroups based on
the DNA methylation profiles: CIMPhigh, CIMPlow, or non-CIMP
(Hinoue et al., 2012). Remarkably, we found that low doses of
5-AZA-CdR can strongly reduce the frequency of colorectal
CICs independent of the CIMP profile, suggesting that this effect
is elicited without demethylation of aberrantly methylated CpG
islands.
Our data suggest that the durable anti-tumor effect of low-
dose 5-AZA-CdR is actually mediated by induction of dsRNAsand activation of MDA5 RNA recognition receptor, followed by
downstream activation of MAVS, IRF7, and type III IFNs and up-
regulation of interferon-responsive genes, independent of their
promoter demethylation. Moreover, clinical trials in non-small-
cell lung cancer, breast cancer, and colorectal cancer patients
with low-dose DNA-demethylating agents also identified upre-
gulation of interferon-responsive genes (Li et al., 2014; Wrangle
et al., 2013), highlighting the clinical relevance of our results.
MDA5 is a pattern-recognition receptor (PRR) ubiquitously ex-
pressed in the cytoplasm ofmost human cells. MDA5 recognizes
nucleic acids associated with viral infections (dsRNAs) and has
two amino-terminal caspase recruitment domains (CARDs).
The CARDs of MDA5, upon activation, can recruit the signaling
adaptor protein MAVS (also known as IPS1, CARDIF, or VISA),
which resides in the outer mitochondrial membrane. MAVS
induces signaling cascades that result in nuclear translocation
of IRF7 and activation of antiviral response programs, such as
immunogenic cell death for viral clearance (Barbalat et al.,
2011). Recent data suggest that the activation of RIG1 and
MDA5 in tumor cells can also induce immunogenic cell death
in melanoma, AML, and pancreatic cancer models (Besch
et al., 2009; Duewell et al., 2014; Jiang et al., 2011). Moreover,
this anti-tumor effect of RIG1/MDA5 signaling seems to be
independent of type I interferon (Besch et al., 2009), similar to
our results with 5-AZA-CdR.
Our data suggest that the 5-AZA-CdR-mediated activation of
MDA5/MAVS/IRF7 pathway is a result of dsRNA induction of
endogenous retrovirus (ERVs). This is in line with previous ana-
lyses suggesting that 5-AZA-CdR treatment could potentially
induce dsRNAs by RNA polymerase III-driven bidirectional tran-
scription of repetitive elements (Leonova et al., 2013) and with
previous results showing that 5-AZA-CdR treatment can induce
the expression of interferon-responsive genes and endogenous
retrovirus (Karpf et al., 1999, 2004). Therefore, low-dose 5-AZA-
CdR treatment will ‘‘trick’’ cancer cells into behaving as virus-
infected cells, inducing an MDA5/MAVS/IRF7-dependent ‘‘viral
mimicry’’ state.
Altogether, our results showing that low-dose 5-AZA-CdR
targets colorectal CICs may explain the delayed response timeCell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc. 971
observed in patients undergoing clinical trials. Moreover, our
results showing that the activation of MDA5/MAVS/IRF7
pathway by dsRNAs is the main mechanism responsible for
the anti-tumor effects of low-dose 5-AZA-CdR may explain the
current absence of DNA methylation markers for patient
response. Monitoring dsRNA formation or MDA5/MAVS/IRF7
pathway activation may thereby be a better predictor of patient
response than monitoring DNA methylation of promoters or
gene bodies. Furthermore, our results suggest that by targeting
the colorectal CICs, low-dose 5-AZA-CdR treatment may
improve patient response to debulking therapies, such as stan-
dard of care chemotherapy, known to spare the CICs (Wicha,
2014). Remarkably, our results identify RIG1 andMDA5 cytosolic
pattern recognition receptors as druggable targets against colo-
rectal CICs.
EXPERIMENTAL PROCEDURES
See the Supplemental Experimental Procedures for detailed experimental
procedures.
Chemical Treatment and Doubling Time Measurement
For each experiment, cells were plated 24 hr prior treatment. At day 0, cells
were treated or mock treated with 5-AZA-CdR (0.3 mM; Sigma Aldrich). Cells
were washed 24 hr after treatment and replenished with fresh media (without
drug). Where indicated, Ruxolitinib (JAK1/JAK2 inhibitor) or CP-690550 (JAK3
inhibitor) was added at a concentration of 1 mg/ml. At the subsequent time
points, cells were harvested, re-suspended, and counted; a fraction of cells
were re-plated for the subsequent point. Doubling time (in days) was estimated
as follows:
Doubling time=ALOGð2Þ=ðLOGðBÞ­LOGðCÞÞ;
where A is the number of days since the cells were plated, B is the total number
of cells when the cells were harvested, and C is the number of cells plated.
Total RNA Isolation, dsRNA Enrichment, and Real-Time PCR
Total RNA was extracted using TRIzol reagent. Primers are listed in Table S1.
For dsRNA enrichment, RNA were treated or not for 30 min with 50 mg/ml
RNaseA in high-salt concentration (NaCl, 0.35 M) to prevent dsRNA degrada-
tion (Life Technology). After treatment, RNase A was removed by RNA purifi-
cation with TRIzol reagent. The thermal cycling protocol was one cycle at
95C for 10 min and then 40 cycles at 95C for 15 s, 60C for 1 min, followed
by a melting curve analysis. For each transcript, the efficiency of the PCR
reaction was determined by the slope of the standard curve generated from
a serial dilution. Each transcript level was normalized by the acidic ribosomal
phosphoprotein P0 (RPLP0) housekeeping gene. For dsRNA enrichment,
expression was normalized by b-actin (ssRNA).
Semi-denaturing Detergent Agarose Gel Electrophoresis
Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) was
performed as previously described (Halfmann and Lindquist, 2008). Briefly,
mitochondria were isolated (Qproteome Mitochondria Isolation Kit,
Quiagen) from LIM1215 cells, resuspended in mitochondria buffer, and
diluted before loading on a 1.5% agarose gel with 43 sample buffer (2X
TAE 20% glycerol 8% SDS, bromophenol blue). Electrophoresis was
done at 4C at a constant voltage of 100 V in running buffer (1XTBE and
0.1% SDS) for 1 hr. Proteins were then transferred into a nitrocellulose
membrane, and MAVS protein was detected using anti-MAVS antibody
(1/1,000; Abcam).
Limiting Dilution Assay
For in vitro LDAs, colorectal cancer cells were treated or not with 5-AZA-CdR
for 1 day, or transfected with 0.5 mg/ml of poly(I:C) low and high molecular972 Cell 162, 961–973, August 27, 2015 ª2015 Elsevier Inc.weight in LyoVec, (InvivoGen) or treated with flagellin 1 mg/ml or transfected
0.5 mg/ml of cGAMP in LyoVec (Invivogen) for 3 days were dissociated into
single cells. Cells were then seeded in 96-well plates at the indicated cell doses
(1, 10, 100, and 1,000 cells/well). Trypan Blue was used to exclude dead cells.
For each cell dose, at least 18 wells were seeded with cells, and for the lower
cell doses, at least 72 wells were plated. 4 weeks later, wells containing
spheres were scored, and the number of positive wells was used to calculate
the frequency of sphere-forming units using the Extreme Limiting Dilution Anal-
ysis (ELDA) software (http://bioinf.wehi.edu.au/software/elda/index.html),
provided by the Walter and Eliza Hall Institute (Hu and Smyth, 2009). The
patient-derived colorectal CICs (#92, #181, and #73) were cultured as previ-
ously described (Kreso et al., 2014). Human colorectal cancer tissue was
obtained with patient consent, as approved by the Research Ethics Board at
the University Health Network.
For in vivo LDAs, LIM1215 cells were treated with and without 5-AZA-CdR
for 24 hours. Following, single cells suspension was obtained and diluted seri-
ally to the desired cell doses. Cells were injected subcutaneously into the
flanks of NSG mice. The number of tumors formed out of the number of sites
injected was scored to determine the frequency of colorectal CICs calculated
using the ELDA software. Animal work was carried out in compliance with the
ethical regulations approved by the Animal Care Committee, University Health
Network, Toronto, Ontario, Canada.
Statistical Analysis
LDA statistical analyses were performed using a pairwise chi-square test
within the ELDA software as previously described (Hu and Smyth, 2009).
Pathway enrichment analysis and upstream regulators statistical analysis
were performed using Fisher’s exact test right-tailed within the IPA software
as previously described (Kra¨mer et al., 2014).
The statistical analysis to compare the frequency distribution was performed
using a Kolmogorov-Smirnov test of frequency distribution data using Graph-
Pad prism software. All other statistical analyses were performed using the
GraphPad prism software.
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